Fruquintinib combined with Serplulimab

Phase 2Monoclonal antibody

Fruquintinib combined with Serplulimab is one of 4 small molecule programs targeting Non-Clear Cell Renal Cell Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Clear Cell Renal Cell CarcinomaActive, not recruiting

Non-Clear Cell Renal Cell CarcinomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

3 competitors in Non-Clear Cell Renal Cell Carcinoma

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

1 2

Opdivo

Bristol-Myers Squibb

Phase 3

1 3

XL092

Roche

Phase 3

1 4

Fruquintinib combined with Serplulimab

RRenJi Hospital

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

Phase 2Active, not recruiting

Non-Clear Cell Renal Cell Carcinoma

NCT05831891

Clinical

Trials by Indication[1]

Non-Clear Cell Renal Cell Carcinoma1 trial

A Multicenter, Single-Arm, Phase II Study Evaluating the Efficacy and Safety of Fruquintinib Combined With Serplulimab as First-Line Treatment in Patients With Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma

Active, not recruiting·RRenJi Hospital·Phase 2·NCT05831891·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Fruquintinib combined with Serplulimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fruquintinib combined with Serplulimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fruquintinib combined with Serplulimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — RenJi Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: RRenJi Hospital

Fruquintinib combined with Serplulimab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

Non-Clear Cell Renal Cell Carcinoma1 trial

References

Drug Info

Quick Facts

Related News